血栓调节蛋白的功能及临床治疗研究进展.pdfVIP

第 卷 第 期 临床药物治疗杂志 13 1 Vol.13,No.1 2015年 1月 Clinical Medication Journal Jan,2015 17(8): 952-960. [14] Lv J, Zhang H, Cui Z, et al. Delayed severe pneumonia in mycophenolate [7] Huang J, Liu G, Zhang Y M, et al. Plasma soluble rokinase receptor mofetil-treated patients with IgA nephropathy[J]. Nephrol Dial levels are increased but do not distinguish primary from secondary focal Transplant, 2008, 23(9):2868-2872. segmental glomerulosclerosis[J]. Kidney Int, 2013 ,84(2):366-372. [15] Liu W X, Li D M, Xu G S, et al. Comparison of the therapeutic [8] 周福德 , 王海燕 . 难治性肾病综合征 [J]. 继续医学教育, 2006, effects of leflunomide and mycophenolate mofetil in the treatment 20(5):16-20. of immunoglobulin A nephropathy manifesting with nephrotic [9] 金有豫 . 药理学 [M]. 5 版 . 北京：人民卫生出版社，2001: 402-407. syndrome[J]. Int J Clin Pharmcol Ther, 2010, 48(8):509-513. [10] Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton [16] Zhou J, Zhang Y, Liu G, et al. Efficacy and safety of leflunomide of kidney podocytes is a direct target of antiproteinuric effect of in treatment of steroid-dependent and steroid-resistant adult onset cyclosporine A[J]. Nat Med, 2008, 14(9):931-938. minimal change disease[J]. Clin Nephrol, 2013, 80(2):121-129. [11] 专家协作组 . 环孢素 A 治疗肾小球疾病的应用共